Flashy Stock: Amedisys, Inc. (NASDAQ: AMED)

Amedisys, Inc. (NASDAQ: AMED) noted an up move of 0.62% in most recent trading session with finishing price of $149.25. The company negotiated 157647 shares compared to an average volume of 265.14K shares. EPS growth for this year is 135.60% and EPS growth for next year is estimated to reach at 8.28%. EPS growth in past five years was 26.10% while EPS growth in next five years is projected to arrive at 16.45%. Sales growth past 5 years was measured at 5.90%.

Amedisys, Inc. (AMED) recently stated its financial results for the three and nine-month periods ended September 30, 2019.

Three Month Periods Ended September 30, 2019 and 2018

• Net service revenue increased $77.3M to $494.6M contrast to $417.3M in 2018.
• Net income attributable to Amedisys, Inc. of $34.1M contrast to $31.4M in 2018.
• Net income attributable to Amedisys, Inc. per diluted share of $1.03 contrast to $0.96 in 2018.

Adjusted Quarterly Results*

• Adjusted EBITDA of $56.8M contrast to $45.3M in 2018.
• Adjusted net service revenue of $494.6M contrast to $417.3M in 2018.
• Adjusted net income attributable to Amedisys, Inc. of $37.9M contrast to $30.9M in 2018.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.15 contrast to $0.95 in 2018.

Nine Month Periods Ended September 30, 2019 and 2018

• Net service revenue increased $226.7M to $1,454.9M contrast to $1,228.2M in 2018.
• Net income attributable to Amedisys, Inc. of $99.2M contrast to $91.9M in 2018.
• Net income attributable to Amedisys, Inc. per diluted share of $3.01 contrast to $2.71 in 2018.

Adjusted Year to Date Results*

• Adjusted EBITDA of $173.0M contrast to $136.7M in 2018.
• Adjusted net service revenue of $1,460.9M contrast to $1,229.9M in 2018.
• Adjusted net income attributable to Amedisys, Inc. of $114.2M contrast to $92.3M in 2018.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $3.47 contrast to $2.73 in 2018.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our third quarter results and our continued outperformance this year. All three of our lines of business continue to grow; we have made great progress integrating the Compassionate Care acquisition; and most importantly, we are once again near the top of the industry in quality for both Home Health and Hospice. We could not achieve such results without the unwavering efforts of all of our 21,000 employees and I want to thank each of you for your continued dedication to our mission of providing clinically excellent care to all of our patients, wherever they call home.”

Analyst recommendation for this stock stands at 2.1. The volatility in the previous week has experienced by 2.92% and observed of 3.12% in the previous month. 90.20% ownership is held by institutional investors while insiders hold ownership of 0.80%. In the trailing 12 months period, return on assets ratio of the Company was 11.70% and return on equity ratio was 23.40% while its return on investment ratio was 23.60%.